In this GEN Learning Lab, our expert panelists Linda Orzolek, MS, MB, Xuhuai Ji, MD, PhD, and Christina Chang, PhD, will discuss the current landscape of imaging- and next-generation sequencing-based ...

Neurodegenerative diseases affect more than 57 million people globally. The incidence of these diseases, from Alzheimer's to Parkinson's to ALS and beyond, is expected to double every 20 years. Though ...

Single-cell omics is a transformative area within life sciences, enabling researchers to untangle cellular heterogeneity, uncover developmental lineages, ...

Researchers create a massive single-cell atlas of the aging mouse brain, revealing how epigenetic changes and "jumping genes" drive neurodegeneration.

Salk researchers create epigenetic atlas of cell type-specific changes in the aging mouse brain, representing eight different brain regions and 36 different cell types to show clear epigenetic ...

Neurodegenerative diseases affect more than 57 million people globally. The incidence of these diseases, from Alzheimer's to Parkinson's to ALS and beyond, is expected to double every 20 years.

AGBT is also, increasingly, a showcase for instruments for spatial biology, a fast-growing field that involves pinpointing the location of RNA and protein molecules en masse. Tarbox calls the meeting ...

How does a tiny cluster of cells become an embryo with a head, trunk, and tail? And how do thousands of genes coordinate this development? A new imaging method makes it possible to visualize the ...

Learn about comparative gene expression studies in Alzheimer's disease and other conditions in Mayo Clinic's Precision Medicine in Neurodegeneration Lab.

Proteomics technologies are expanding rapidly due to advances in mass spectrometry, AI-driven analysis, and single-cell approaches. Growing investment and new applications in drug discovery and ...

Using single-cell sequencing, researchers found distinct immune profiles in different CNS tumors, highlighting its potential as a prognostic tool.

Immunotherapy has revolutionized cancer treatment, yet response rates remain highly variable across tumor types and individual patients. Increasing evidence ...